Product Name :
BAY-1797
Description:
BAY-1797 is a potent, orally active, and selective P2X4 antagonist, with an IC50 of 211 nM against human P2X4. BAY-1797 displays no or very weak activity on the other P2X ion channels. BAY-1797 shows anti-nociceptive and anti-inflammatory effects.
CAS:
2055602-83-8
Molecular Weight:
416.88
Formula:
C20H17ClN2O4S
Chemical Name:
N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide
Smiles :
NS(=O)(=O)C1=CC(=CC=C1OC1=CC(Cl)=CC=C1)NC(=O)CC1C=CC=CC=1
InChiKey:
CSJYMAFXYMYNCK-UHFFFAOYSA-N
InChi :
InChI=1S/C20H17ClN2O4S/c21-15-7-4-8-17(12-15)27-18-10-9-16(13-19(18)28(22,25)26)23-20(24)11-14-5-2-1-3-6-14/h1-10,12-13H,11H2,(H,23,24)(H2,22,25,26)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
BAY-1797 is a potent, orally active, and selective P2X4 antagonist, with an IC50 of 211 nM against human P2X4. BAY-1797 displays no or very weak activity on the other P2X ion channels. BAY-1797 shows anti-nociceptive and anti-inflammatory effects.|Product information|CAS Number: 2055602-83-8|Molecular Weight: 416.88|Formula: C20H17ClN2O4S|Chemical Name: N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide|Smiles: NS(=O)(=O)C1=CC(=CC=C1OC1=CC(Cl)=CC=C1)NC(=O)CC1C=CC=CC=1|InChiKey: CSJYMAFXYMYNCK-UHFFFAOYSA-N|InChi: InChI=1S/C20H17ClN2O4S/c21-15-7-4-8-17(12-15)27-18-10-9-16(13-19(18)28(22,25)26)23-20(24)11-14-5-2-1-3-6-14/h1-10,12-13H,11H2,(H,23,24)(H2,22,25,26)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 250 mg/mL (599.69 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|BAY-1797 inhibits human, mouse, and rat P2X4 in 1321N1 cells with IC50s of 108 nM, 112 nM, and 233 nM, respectively.{{Carbamazepine} site|{Carbamazepine} HDAC|{Carbamazepine} Protocol|{Carbamazepine} In Vivo|{Carbamazepine} manufacturer|{Carbamazepine} Epigenetics} BAY-1797 exerts no measurable activity on hERG and carbonic anhydrase II (both IC50>10 μM).{{Gimeracil} web|{Gimeracil} Biological Activity|{Gimeracil} Data Sheet|{Gimeracil} custom synthesis|{Gimeracil} Autophagy} BAY-1797 is also tested against a panel of off-targets, including G-protein coupled receptors (GPCRs), ion channels, kinases, and transporters at 10 μM.PMID:33228997 An inhibitory activity against the dopamine transporter (DAT, IC50 2.17 μM) was revealed as the only hit.|In Vivo:|BAY-1797 (12.5-50 mg/kg; p.o.) shows a significant induction of PGE2 levels in the inflamed paw in the mouse Complete Freund’s Adjuvant (CFA) inflammatory pain model. BAY-1797 (50 mg/kg; once daily for multiple p.o. administrations) induces a significant reduction of the ipsilateral paw load 24 and 48 h after CFA injection. BAY-1797 treatment shows the AUCnorm, Vss and t1/2 are 1.06 kg h/L, 3.67 L/kg and 2.64 hours, respectively.|Products are for research use only. Not for human use.|